acalabrutinib
E888598
Bruton tyrosine kinase inhibitor
protein kinase inhibitor
second-generation BTK inhibitor
small molecule drug
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
All labels observed (1)
| Label | Occurrences |
|---|---|
| acalabrutinib canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T10837768 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: acalabrutinib Context triple: [Bruton tyrosine kinase, isTherapeuticTargetOf, acalabrutinib]
-
A.
Venclexta
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: acalabrutinib Target entity description: Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
A.
Venclexta
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
Statements (53)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton tyrosine kinase inhibitor
ⓘ
protein kinase inhibitor ⓘ second-generation BTK inhibitor ⓘ small molecule drug ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| ATCCode | L01EL02 ⓘ |
| bindingSite |
Cys481 of BTK
ⓘ
linked to:
BTK
|
| bioavailability | oral, moderate ⓘ |
| blackBoxWarning | none ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
fatigue ⓘ headache ⓘ myalgia ⓘ upper respiratory tract infection ⓘ |
| contraindication | known hypersensitivity to acalabrutinib ⓘ |
| developedBy |
Acerta Pharma
ⓘ
AstraZeneca ⓘ |
| dosageForm |
oral capsule
ⓘ
oral tablet ⓘ |
| drugInteraction |
strong CYP3A inducers
ⓘ
strong CYP3A inhibitors ⓘ |
| eliminationHalfLife | approximately 1 hour ⓘ |
| FDAApprovalDate | 2017-10-31 ⓘ |
| FDADesignation | orphan drug for mantle cell lymphoma ⓘ |
| hasActiveMetabolite | ACP-5862 ⓘ |
| hasCASNumber | 1420477-60-6 ⓘ |
| hasHigherSelectivityThan | ibrutinib ⓘ |
| hasINN | acalabrutinib ⓘ |
| hasMolecularFormula | C26H23N7O2 ⓘ |
| hasMolecularWeight | 465.51 g/mol ⓘ |
| hasSelectivityFor | BTK over other kinases ⓘ |
| hasTradeName |
Calquence
ⓘ
linked to:
Imbruvica
|
| hasUSAN | acalabrutinib ⓘ |
| indication |
chronic lymphocytic leukemia
ⓘ
mantle cell lymphoma ⓘ previously untreated chronic lymphocytic leukemia ⓘ relapsed or refractory mantle cell lymphoma ⓘ small lymphocytic lymphoma ⓘ
linked to:
chronic lymphocytic leukemia
|
| isSecondGenerationComparedTo |
ibrutinib
ⓘ
linked to:
Imbruvica
|
| legalStatusInEuropeanUnion | prescription only ⓘ |
| legalStatusInUnitedStates | prescription only ⓘ |
| mechanismOfAction | irreversible covalent inhibition of Bruton tyrosine kinase ⓘ |
| metabolism | hepatic ⓘ |
| pregnancyCategory | may cause fetal harm (based on mechanism and animal data) ⓘ |
| primaryMetabolizingEnzyme | CYP3A4 ⓘ |
| proteinBinding | high ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousAdverseEffect |
atrial fibrillation
ⓘ
cytopenias ⓘ hemorrhage ⓘ infections ⓘ |
| targets | Bruton tyrosine kinase ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: acalabrutinib Description of subject: Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.